Compumedics Ltd
ASX:CMP

Watchlist Manager
Compumedics Ltd Logo
Compumedics Ltd
ASX:CMP
Watchlist
Price: 0.28 AUD Market Closed
Market Cap: AU$55.9m

EV/EBITDA

18.7
Current
319%
Cheaper
vs 3-y median of -8.6

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
18.7
=
Enterprise Value
AU$65.3m
/
EBITDA
AU$3.1m

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
18.7
=
Enterprise Value
AU$65.3m
/
EBITDA
AU$3.1m

Valuation Scenarios

Compumedics Ltd is trading below its 5-year average

If EV/EBITDA returns to its 5-Year Average (20.5), the stock would be worth AU$0.31 (10% upside from current price).

Statistics
Positive Scenarios
2/3
Maximum Downside
-12%
Maximum Upside
+36%
Average Upside
11%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 18.7 AU$0.28
0%
5-Year Average 20.5 AU$0.31
+10%
Industry Average 25.5 AU$0.38
+36%
Country Average 16.5 AU$0.25
-12%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
AU$65.3m
/
Jan 2026
AU$3.1m
=
18.7
Current
AU$65.3m
/
Jun 2026
AU$7.3m
=
9
Forward
AU$65.3m
/
Jun 2027
AU$13.5m
=
4.8
Forward
AU$65.3m
/
Jun 2028
AU$17.7m
=
3.7
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
AU
Compumedics Ltd
ASX:CMP
55.9m AUD 18.7 495
US
Abbott Laboratories
NYSE:ABT
168.1B USD 14.6 26.8
US
Intuitive Surgical Inc
NASDAQ:ISRG
166.6B USD 44.2 58.3
US
Stryker Corp
NYSE:SYK
131.3B USD 20.6 40.5
IE
Medtronic PLC
NYSE:MDT
110.6B USD 13.3 24
US
Boston Scientific Corp
NYSE:BSX
95.3B USD 19.5 32.9
DE
Siemens Healthineers AG
XETRA:SHL
43.9B EUR 11.6 20.8
US
Edwards Lifesciences Corp
NYSE:EW
47B USD 23.9 43.8
US
IDEXX Laboratories Inc
NASDAQ:IDXX
47B USD 31.3 44.3
US
Becton Dickinson and Co
NYSE:BDX
45.1B USD 10.1 25.7
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
34B USD 11.7 16.3

Market Distribution

In line with most companies in Australia
Percentile
58th
Based on 1 243 companies
58th percentile
18.7
Low
0 — 10
Typical Range
10 — 24.5
High
24.5 —
Distribution Statistics
Australia
Min 0
30th Percentile 10
Median 16.5
70th Percentile 24.5
Max 6 797.5

Compumedics Ltd
Glance View

Market Cap
55.9m AUD
Industry
Health Care

Compumedics Ltd. is engaged in the research, development, manufacture and distribution of medical equipment. The company is headquartered in Melbourne, Victoria. The company went IPO on 2000-12-21. The firm is engaged in development, manufacture and commercialization of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The firm sells all its product offerings, including sleep diagnostic systems, clinical EEG systems, brain monitoring systems, ultra-sonic blood-flow systems, supplies and technical service and support. The firm sell its products throughout America’s, Australia and Asia Pacific, and Europe and the Middle East regions. Its United States business also includes sleep diagnostic services business. The firm product includes ONsight A.V.S., Grael PSG, Grael LT EEG System, Siesta 802, Grael 4K PSG:EEG, Grael 4K-EEG, Neuvo 64-512 Channel LTM EEG and CURRY. The Company’s subsidiaries include Compumedics USA Ltd, DWL USA Inc., Compumedics USA Inc, Compumedics Telemed Pty Ltd, Compumedics Medical Innovation Pty Ltd, Compumedics Cardiology Pty Ltd.

CMP Intrinsic Value
0.62 AUD
Undervaluation 55%
Intrinsic Value
Price AU$0.28
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett